Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational Studies

Otolaryngol Head Neck Surg. 2019 Feb;160(2):368. doi: 10.1177/0194599818813521.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Angiogenesis Inhibitors
  • Bevacizumab
  • Epistaxis
  • Humans
  • Telangiectasia, Hereditary Hemorrhagic*

Substances

  • Angiogenesis Inhibitors
  • Bevacizumab